Allergy Towards Grass and Bronchial Inflammation - Related to Immunotherapy and Exhaled Nitrogen Oxide

The recruitment status of this study is unknown because the information has not been verified recently.
Verified September 2006 by Bispebjerg Hospital.
Recruitment status was  Recruiting
Sponsor:
Information provided by:
Bispebjerg Hospital
ClinicalTrials.gov Identifier:
NCT00312312
First received: April 5, 2006
Last updated: June 11, 2007
Last verified: September 2006

April 5, 2006
June 11, 2007
March 2006
Not Provided
  • Skin prick test
  • Spirometry
  • Methacholine provocation of the pulmonary system
  • Exhaled nitric oxide
  • Immunoglobulin E (IgE) status
  • Sputum examination
  • Condensation of exhaled air
  • Skin prik test
  • Spirometry
  • Methacholine provocation of the pulmonary system
  • Exhaled nitric oxide
  • IgE status
  • Sputum examination
  • Condensation of exhaled air
Complete list of historical versions of study NCT00312312 on ClinicalTrials.gov Archive Site
Questionnaire
Same as current
Not Provided
Not Provided
 
Allergy Towards Grass and Bronchial Inflammation - Related to Immunotherapy and Exhaled Nitrogen Oxide
Does Specific Immunotherapy Possess Immunomodulative Effects at the Bronchial Mucosa Level Among Adults With Atopic Diseases?

The purpose of this study is to evaluate the immunomodulatory effect of treatment of allergic rhinitis symptoms with specific immunotherapy by measurement of pulmonary inflammatory markers, and among others, exhaled nitric oxide.

Not Provided
Interventional
Not Provided
Allocation: Non-Randomized
Endpoint Classification: Efficacy Study
Intervention Model: Parallel Assignment
Masking: Open Label
Primary Purpose: Prevention
  • Asthma, Bronchial
  • Allergic Rhinitis
  • Hypersensitivity, Immediate
Biological: Specific immunotherapy
Not Provided
Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Recruiting
40
December 2008
Not Provided

Inclusion Criteria:

  • Age 18-45 years old
  • Skin prick test or RAS test and physical examination conclude that the patient will have a beneficial effect from specific immunotherapy

Exclusion Criteria:

  • Other diseases except atopic disease
  • Pregnancy
Both
18 Years to 45 Years
No
Contact: Thomas B Knudsen, Medical student +45 61 70 96 99 thomas@uknet.dk
Contact: Vibeke Backer, M.D., M.D.Sci +45 35 31 30 69 backer@dadlnet.dk
Denmark
 
NCT00312312
SITNO
Not Provided
Not Provided
Bispebjerg Hospital
Not Provided
Principal Investigator: Vibeke Backer, M.D., M.D.Sci Lungeforskningsenheden v/Bispebjerg hospital
Bispebjerg Hospital
September 2006

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP